×
About 4,550 results

ALLMedicine™ Hypokalemia Center

Research & Reviews  1,086 results

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated ...
https://doi.org/10.1016/S1470-2045(21)00658-6
The Lancet. Oncology; Schoenfeld JD, Giobbie-Hurder A et. al.

Jan 17th, 2022 - Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benef...

Hypokalemia Measurement and Management in Patients With Status Asthmaticus on Continuou...
https://doi.org/10.1542/hpeds.2021-006265
Hospital Pediatrics; Cox C, Patel K et. al.

Jan 13th, 2022 - Status asthmaticus is commonly treated in pediatric patients by using continuous albuterol, which can cause hypokalemia. The primary aim of this study was to determine if serial potassium monitoring is necessary by examining treatment frequency of...

Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma p...
https://doi.org/10.1530/ERC-21-0202
Endocrine-related Cancer; Haberbosch L, Maurer L et. al.

Jan 12th, 2022 - Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a poor prognosis. Mitotane, a derivative of the pesticide DDT, has been used successfully as first line chemotherapy since the 1960s, if maintained within a narrow therapeutic wind...

Vomiting, electrolyte disturbance, and medications; the perfect storm for acquired long...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751273
Journal of Medical Case Reports; Tiver KD, Dharmaprani D et. al.

Jan 12th, 2022 - Acquired long QT syndrome is an important and preventable cause of cardiac arrest. Certain medications and electrolyte disturbance are common contributors, and often coexist. In this case, we report five contributors to cardiac arrest. This case i...

Type 1 Diabetes Mellitus Clinical Presentation
http://emedicine.medscape.com/article/117739-clinical

Jan 11th, 2022 - History The most common symptoms of type 1 diabetes mellitus (DM) are polyuria, polydipsia, and polyphagia, along with lassitude, nausea, and blurred vision, all of which result from the hyperglycemia itself. Polyuria is caused by osmotic diuresis...

see more →

Guidelines  1 results

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an end...
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.

Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...

see more →

Drugs  500 results see all →

Clinicaltrials.gov  24 results

Occurrence of Dyskalemia With Treatment for Hypertension
https://clinicaltrials.gov/ct2/show/NCT05155436

Dec 13th, 2021 - Hypertension affects an estimated 1.04 billion people in low- and middle-income countries, with an estimated increase in prevalence of 7.7% between 2000 and 2010.1 Hypertension treatment and control may lower the risk of cardiovascular disease and...

Amiloride in Nephrotic Syndrome
https://clinicaltrials.gov/ct2/show/NCT05079789

Oct 15th, 2021 - The monocenter randomized-controlled AMILOR trial investigates the efficacy of the ENaC blocker amiloride in reducing edema in nephrotic syndrome compared with standard therapy with the loop diuretic furosemide. Patients with acute nephrotic syndr...

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT03574363

Oct 4th, 2021 - The study will enroll up to 165 patients, randomized in a 1:1:1 ratio to 1 of 3 treatment groups (55 patients in each group): KBP-5074 0.25 mg once daily (QD), KBP-5074 0.5 mg QD, or placebo QD. Randomization will be stratified to balance enrollme...

Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study
https://clinicaltrials.gov/ct2/show/NCT04207203

May 26th, 2021 - Feasibility, descriptive single arm open-label interventional trial lasting 6 weeks. The study will recruit 36 CKD patients at the outpatient clinic with: age between 18 to 85 years; glomerular filtration rate < 29 ml/min/1.73 m2 and not on dialys...

The Correlation Between Sleep Quality and Atrial Fibrillation Undergoing High-flow Nasal Cannula Oxygen (HFNC)
https://clinicaltrials.gov/ct2/show/NCT02713737

Mar 9th, 2021 - Atrial fibrillation (AF) has been reported to occur in up to 20-40% of patients undergoing coronary artery bypass grafting (CABG). Postoperative AF plays a major role in the determination of hemodynamic deterioration and can be associated with thr...

see more →

News  208 results

Aspacytarabine Shows Efficacy, Safety in Newly Diagnosed AML Unfit for Intensive Therapy
https://www.onclive.com/view/aspacytarabine-shows-efficacy-safety-in-newly-diagnosed-aml-unfit-for-intensive-therapy

Jan 10th, 2022 - The novel antimetabolite aspacytarabine (BST-236) was found to produce a complete remission (CR) rate of 37% in adult patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive therapy, according to data from a phase 2b...

FDA OKs First Drug for Aggressive, Ultra-Rare Sarcoma
https://www.medpagetoday.com/hematologyoncology/othercancers/95831

Nov 23rd, 2021 - The FDA approved nab-sirolimus (Fyarro) on Tuesday for the treatment of malignant perivascular epithelioid cell tumors (PEComa), a rare and aggressive form of sarcoma. Nab-sirolimus, an albumin-bound mTOR inhibitor, is indicated for patients with ...

Pembrolizumab Plus Gemcitabine/Hypofractionated Radiotherapy Demonstrates Promising Efficacy in Muscle-Invasive Bladder Cancer
https://www.onclive.com/view/pembrolizumab-plus-gemcitabine-hypofractionated-radiotherapy-demonstrates-promising-efficacy-in-muscle-invasive-bladder-cancer

Jun 7th, 2021 - Pembrolizumab (Keytruda) in combination with gemcitabine and concurrent hypofractionated radiotherapy (RT) appears to be a promising and efficacious, bladder-sparing regimen for patients with muscle-invasive bladder cancer (MIBC), according to fin...

Patritumab Deruxtecan Displays Durable Efficacy in EGFR TKI–Resistant EGFR+ NSCLC
https://www.onclive.com/view/patritumab-deruxtecan-displays-durable-efficacy-in-egfr-tki-resistant-egfr-nsclc

Jun 4th, 2021 - Patritumab deruxtecan (U3-1402) was found to induce clinically meaningful, durable efficacy in heavily pretreated patients with EGFR-mutated non–small cell lung cancer (NSCLC) who were resistant to EGFR TKIs, according to data from a phase 1 study...

Cushing Death Rate 'Unacceptable,' Triple That of General Population
https://www.medscape.com/viewarticle/949257

Apr 14th, 2021 - Excess mortality among people with endogenous Cushing syndrome (CS) has declined in the past 20 years yet remains three times higher than in the general population, new research finds. Among more than 90,000 individuals with endogenous CS, the ove...

see more →

Patient Education  1 results see all →